FY2028 EPS Estimates for Cytosorbents Cut by HC Wainwright

Cytosorbents Corporation (NASDAQ:CTSO) – Analysts at HC Wainwright dropped their FY2028 earnings estimates for Cytosorbents in a report issued on Thursday, March 26th. HC Wainwright analyst S. Lee now expects that the medical research company will post earnings of ($0.04) per share for the year, down from their previous forecast of ($0.03). The consensus estimate for Cytosorbents’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Cytosorbents’ FY2029 earnings at ($0.02) EPS.

A number of other research firms also recently issued reports on CTSO. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cytosorbents in a report on Friday, January 9th. D. Boral Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a report on Thursday, March 26th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $5.38.

Cytosorbents Stock Down 5.6%

Cytosorbents stock opened at $0.56 on Monday. The firm has a market capitalization of $35.16 million, a price-to-earnings ratio of -4.31 and a beta of 1.36. The firm’s fifty day moving average price is $0.68 and its two-hundred day moving average price is $0.75. Cytosorbents has a 1-year low of $0.50 and a 1-year high of $1.39. The company has a current ratio of 2.11, a quick ratio of 1.71 and a debt-to-equity ratio of 1.61.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings data on Wednesday, March 25th. The medical research company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.04). Cytosorbents had a negative net margin of 22.12% and a negative return on equity of 131.86%. The firm had revenue of $9.23 million for the quarter, compared to the consensus estimate of $9.22 million.

Institutional Trading of Cytosorbents

Several hedge funds have recently added to or reduced their stakes in the stock. Avenir Corp boosted its stake in Cytosorbents by 2.9% in the fourth quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock valued at $3,343,000 after acquiring an additional 147,261 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Cytosorbents by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after purchasing an additional 79,535 shares during the last quarter. CM Management LLC raised its holdings in shares of Cytosorbents by 14.6% in the 4th quarter. CM Management LLC now owns 1,476,500 shares of the medical research company’s stock worth $944,000 after purchasing an additional 188,372 shares during the period. CIBC Bancorp USA Inc. bought a new stake in shares of Cytosorbents in the 3rd quarter worth approximately $161,000. Finally, GSA Capital Partners LLP purchased a new position in Cytosorbents in the third quarter valued at approximately $105,000. Institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.